What is the appropriate dosing regimen for colistimethate sodium (colistin) and polymyxin B in a chronic kidney disease patient with an estimated glomerular filtration rate of 12 mL/min/1.73 m² infected with multidrug‑resistant Klebsiella oxytoca?

Dosing Regimen for Colistin/Polymyxin B in CKD Patient with eGFR 12

For your CKD patient with eGFR 12 mL/min/1.73 m², use colistimethate sodium (CMS) at 1.5 mg/kg colistin base activity (CBA) every 36 hours, or consider polymyxin B at 100-150 mg loading dose followed by 50-75 mg every 12 hours with mandatory therapeutic drug monitoring if available.

Colistin (Colistimethate Sodium) Dosing

Severe Renal Impairment (CrCl 10-29 mL/min)

According to FDA labeling, your patient falls into the "severe" renal impairment category 1. The recommended regimen is:

• Dose: 1.5 mg/kg CBA every 36 hours
• Maximum daily dose: Do not exceed 5 mg/kg/day even with normal renal function 1
• Dosing based on: Ideal body weight if patient is obese 1

Critical Dosing Considerations

Loading dose strategy: Recent evidence strongly suggests standard dosing often results in subtherapeutic levels. While FDA labeling doesn't specify a loading dose for severe renal impairment, pharmacokinetic studies demonstrate that patients with preserved renal function require higher initial dosing to achieve target concentrations 2, 3. However, with eGFR 12, the prolonged half-life means accumulation is a significant concern.

Target concentration: Aim for steady-state plasma concentration (Css,avg) of 2 mg/L, though achieving this in severe renal impairment with standard dosing is more feasible than in patients with normal renal function 2.

Dosage Unit Conversion (Critical)

Pay careful attention to unit conversion 4:

• 1 million units = 80 mg CMS mass = 33 mg CBA
• Prescribe in CBA (colistin base activity) to avoid confusion

Polymyxin B as Alternative

Dosing in Severe Renal Impairment

Key advantage: Polymyxin B does not require renal dose adjustment as extensively as colistin, since it undergoes minimal renal elimination 5, 6.

Recommended regimen:

• Loading dose: 100-150 mg (1.5-2 mg/kg) as single dose
• Maintenance dose: 50-75 mg every 12 hours (1-1.5 mg/kg/day divided)
• Adjustment factor: eGFR is a significant covariate affecting clearance, but the effect is less pronounced than with colistin 6

Recent multicenter data shows clearance of 1.68 L/h in ICU patients, with lower clearance in renal impairment requiring dose reduction 6.

Combination Therapy Recommendation

You should strongly consider combination therapy rather than monotherapy 4. Guidelines recommend polymyxin combination therapy as preferential over monotherapy for MDR Gram-negative infections (strong recommendation, moderate-quality evidence) 4.

Combination Options for Klebsiella oxytoca

Since your isolate is only sensitive to colistin/polymyxin B:

1. Polymyxin + Carbapenem: Consider adding high-dose meropenem via extended infusion (3 hours) if MIC ≤8 mg/L, even if reported "resistant" 4. This exploits potential synergy at high concentrations.

2. Polymyxin + Fosfomycin: Demonstrated reduced microbiological failure in RCTs, though mortality benefit unclear 7, 4.

3. Avoid polymyxin + vancomycin: Significantly higher nephrotoxicity without mortality benefit 7.

Monitoring Requirements

Mandatory Monitoring

1. Renal function: Monitor creatinine and urine output daily, as nephrotoxicity is dose-dependent and reversible if caught early 1, 8

2. Therapeutic drug monitoring (TDM): Strongly encouraged where available 7, 4. Target colistin Css of 2 mg/L; for polymyxin B, target steady-state concentration of 2-3 mg/L 5.

3. Neurological symptoms: Watch for circumoral paresthesia, extremity tingling, vertigo, dizziness, or speech slurring 1. These are dose-dependent and may require dose reduction but not discontinuation.

Nephrotoxicity Risk

With eGFR 12, your patient already has severe CKD. Studies show nephrotoxicity rates of 33.9% in CKD patients, but this was reversible in 52.6% of cases 8. The incidence is similar to general population when appropriately dosed, suggesting CMS can be used safely in this population 8.

Avoid concurrent nephrotoxic agents: Do not combine with aminoglycosides, vancomycin, or other nephrotoxic drugs 4.

Clinical Efficacy Expectations

Despite concerns about underdosing in renal impairment, clinical cure rates of 72.9% have been achieved in CKD patients even with lower-than-recommended plasma concentrations 8. This suggests the drug remains effective when dosed appropriately for renal function.

Practical Algorithm

1. Choose agent: Polymyxin B preferred over colistin in severe renal impairment due to less complex dosing
2. Loading dose: Polymyxin B 100-150 mg OR CMS 2.5 mg/kg CBA (if choosing colistin)
3. Maintenance:
   • Polymyxin B: 50-75 mg q12h
   • CMS: 1.5 mg/kg CBA q36h
4. Add combination partner: High-dose extended-infusion meropenem if any possibility of synergy
5. Monitor: Daily creatinine, neurological exam, TDM if available
6. Adjust: Based on TDM results and clinical response

Critical Pitfall to Avoid

Do not use standard dosing recommendations for normal renal function 1. With eGFR 12, drug accumulation will occur rapidly, leading to neurotoxicity and worsening nephrotoxicity. The every-36-hour interval for colistin is essential at this level of renal impairment.